MAPT and Alzheimer disease: This was further confirmed by our group analyses, which showed significant differences in amyloid-β and tau burden not only between patients and controls (which has already been shown by previous studies: Cho et al., 2016a; Johnson et al., 2016; Schöll et al., 2016; Wang et al., 2016), but also between amyloid-β positive and negative controls, and between patients with Alzheimer’s disease and patients with mild cognitive impairment.